Marburg Virus Disease

Marburg virus disease is a severe viral hemorrhagic fever closely related to Ebola virus disease, both being filoviruses, caused by Marburg virus.

It causes a clinically very similar illness to Ebola virus disease, though it is a genetically and antigenically distinct virus, with periodic outbreaks reported predominantly in parts of Africa, and fruit bats (specifically the Egyptian fruit bat) again considered the likely natural reservoir.

Transmission follows the same principal routes as Ebola: direct contact with the blood, body fluids, or secretions of an infected, symptomatic person, or, for initial spillover into the human population, contact with infected bats or their environment, such as through cave or mine exposure in endemic areas.

The clinical course closely mirrors that of Ebola virus disease, and the two are generally clinically indistinguishable without specific laboratory testing.

• Sudden onset fever, severe headache, myalgia, and malaise following an incubation period of roughly 2 to 21 days, similarly non-specific in its early presentation.
• Progression to severe gastrointestinal symptoms, with profuse vomiting and diarrhea, again often a major contributor to the severe fluid and electrolyte derangement seen in this illness.
• A characteristic, though not universal, maculopapular rash has been more specifically described in some accounts of Marburg virus disease.
• Progression, in severe cases, to bleeding manifestations, multi-organ dysfunction, and shock, with case fatality rates that have varied considerably between outbreaks, in some instances reported as very high, again influenced by viral strain and the quality and speed of supportive care and outbreak response available.

• RT-PCR testing of blood, performed under appropriate high biosafety containment given the pathogen risk, is the standard diagnostic approach, mirroring the approach for Ebola virus disease.
• As with Ebola, a detailed epidemiological exposure history, relevant travel or residence in an area with a known or suspected outbreak, or specific exposures such as cave or mine entry in endemic regions, is essential given the non-specific early clinical presentation, and should trigger the same urgent isolation and notification pathway described for Ebola.
• Routine supportive bloods are performed with the same appropriate precautions as for suspected Ebola, given the shared high pathogen risk.

Differentials mirror those for Ebola virus disease: malaria (always test for, and treat if positive, without this excluding concurrent Marburg infection), typhoid fever, and other viral hemorrhagic fevers.

Management follows essentially the same principles as for Ebola virus disease, given the close clinical and epidemiological similarity between the two conditions.

• Immediate isolation and urgent public health notification on clinical suspicion, before extensive further assessment, given the significant onward transmission risk.
• Supportive care remains the foundation of management: aggressive fluid and electrolyte replacement, management of shock, correction of coagulopathy, and treatment of secondary infection, with well delivered supportive care again central to improving survival outcomes.
• Unlike Ebola virus disease, there is currently no licensed specific antiviral or monoclonal antibody treatment with established efficacy specifically for Marburg virus disease, though this is an active area of ongoing research, and investigational therapies developed for filoviruses more broadly may be considered under specific outbreak response or compassionate use protocols where available.
• Similarly, there is currently no licensed vaccine for Marburg virus disease in routine use, though candidate vaccines have been developed and used in an investigational capacity during some outbreak responses, again an evolving area given the relatively recent and rapid progress made with Ebola vaccines.
• Strict infection prevention and control measures are essential throughout, mirroring those described for Ebola virus disease, including appropriate personal protective equipment, safe handling of body fluids and waste, and safe burial practices.

Referral: this is a public health emergency requiring immediate notification and coordination with public health and infectious disease authorities, following the same urgent pathway as for suspected Ebola virus disease; specialist high consequence infectious disease units should be engaged as early as possible.